Alex Frew McMillan
As a free-lancer, he has written regularly for The New York Times, and is a contributor to TheStreet.com and Forbes. He has also written the occasional piece for publications such as The Wall Street Journal, the Financial Times, The Australian, the Economist Intelligence Unit and CNBC.
He covered the September 11, 2001 attacks for CNN, writing the first reaction to the disaster from governments around the world, and wrote a series of well-regarded stories about greater China’s property slowdown for Reuters. His real-estate coverage has explained the importance of property trends for institutional investors as well as for individual property owners. He also covered the hedge-fund industry for six years and has focused on alternative as well as personal finance.
Since moving to Hong Kong from New York City 15 years ago, he has devoted himself to coverage of Asia, writing magazine stories and analysis pieces for Asian Investor, the South China Morning Post and the Straits Times, as well as many magazines. He has also made numerous appearances on both television and radio to discuss his work.
With a South African father and British mother, he took up a Morehead Scholarship to study in the United States, one of the best-known merit scholarships in the country, offered to candidates considered to have leadership potential.
He graduated with a degree in Journalism and English from the University of North Carolina at Chapel Hill, with honors and distinction, and serves as co-chairman of the university's alumni association in Hong Kong. Besides reporting, he is also an avid tennis player, snowboarder and scuba diver, and is a PADI-certified divemaster.
Recent Articles By The Author
India's state-owned enterprises saw share prices soar in the run-up to this year's elections, but recent reforms stalled momentum, so play Indian equities instead.
The conglomerate Fosun will attempt to resuscitate Thomas Cook, one of Britain's most recognizable brands.
Company founders often treat their firms like personal empires even after businesses go public.
Investors should keep tabs on these "focus events" from this quartet of U.S.-listed Japanese drugmakers that can make or break their treatments.
Save for a refusing to budge on climate change, U.S. President Donald Trump left the G-20 in Osaka with something a bit unusual for him: some good news.